Vernalis and Servier in two-year oncology collaboration
Shares in Vernalis rose more than 1% after it and Servier reinforced their partnership by entering into a new two-year oncology drug discovery collaboration on an undisclosed target.
FTSE AIM 100
3,642.48
12:15 26/04/24
n/a
n/a
FTSE AIM All-Share
755.50
12:15 26/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,720.52
12:14 26/04/24
-0.13%
-29.96
Vernalis plc
6.17p
12:19 09/10/18
0.00%
0.00p
This extended the existing seven-year successful collaborations between the pair.
Vernalis would get a €2m upfront payment, fees, research milestones and a share in the downstream success of any products coming out of this new collaboration.
At 10:27 GMT, shares in AIM-quoted Vernalis were up 1.03% to 24.5p each.